11/19/2025 | Press release | Distributed by Public on 11/19/2025 15:58
|
☒
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☐
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
|
|
|
enVVeno Medical Corporation
|
|
(Name of Registrant as Specified in Its Charter)
|
|
N/A
|
|
(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)
|
|
|
|
☒
|
No fee required.
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
|
1.
|
To elect Matthew M. Jenusaitis and Robert A. Berman as Class II Directors of the Company, to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, incapacity, removal or resignation;
|
|
2.
|
To approve on a non-binding, advisory basis the compensation of our named executive officers;
|
|
3.
|
To ratify the appointment by the Audit Committee of the Company's Board of Directors of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;
|
|
4.
|
To approve the adoption of the enVVeno Medical Corporation 2025 Equity Incentive Plan;
|
|
5.
|
To grant authority to the Company's Board of Directors to effectuate a reverse stock split of the Company's common stock at a ratio of between one-for-five and one-for-thirty-five, with such ratio to be determined at the sole discretion of the Board of Directors and with such reverse stock split to be effectuated at such time and date, if at all, as determined by the Board of Directors in its sole discretion; and
|
|
6.
|
To transact, in the discretion of the Company's Board of Directors, such other business as may properly come before the Meeting or any adjournment thereof.
|
|
|
|
|
|
|
|
|
BY ORDER OF THE BOARD OF DIRECTORS,
|
|
|
|
|
||
|
|
|
Robert A. Berman,
Chief Executive Officer
|
|
|
|
|
||
|
|
|
November 19, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prior to
the Reverse
Split
|
|
|
Assuming a
One- for-
Five Reverse
Split
|
|
|
Assuming a
One- for-
Ten Reverse
Split
|
|
|
Assuming a
One- for-
Twenty Reverse
Split
|
|
|
Assuming a
One- for-
Thirty Reverse
Split
|
|
|
Assuming a
One- for-
Thirty-Five Reverse
Split
|
|
|
Aggregate Number of
Shares of common
stock Outstanding
|
|
|
20,216,176
|
|
|
4,043,235
|
|
|
2,021,617
|
|
|
1,010,808
|
|
|
673,872
|
|
|
577,605
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.
|
The name of the Corporation is: enVVeno Medical Corp.
|
|
2.
|
The board of directors of the Corporation (the "Board") duly adopted, by written consent on the 17th day of November, 2025 in accordance with Section 141(f) of the DGCL, a resolution proposing and declaring advisable an amendment to the Fifth Amended and Restated Certificate of Incorporation of said Corporation to consummate a reverse stock split of the Corporation's common stock, par value $0.00001 per share (the "Common Stock"), which such resolution was approved by the stockholders of the Corporation on the ____ day of ________, 202_ at a meeting of the stockholders of the Corporation.
|
|
3.
|
That upon effectiveness of this Certificate of Amendment (the "Split Effective Time"), each share of Common Stock issued and outstanding immediately prior to Split Effective Time shall be automatically changed and reclassified into a smaller number of shares such that each _________ (__) shares of issued Common Stock immediately prior to the Split Effective Time is reclassified into one (1) share of Common Stock. Notwithstanding the immediately preceding sentence, there shall be no fractional shares issued and, in lieu thereof, a holder of Common Stock on the Split Effective Time who would otherwise be entitled to a fraction of a share as a result of the reclassification, following the Split Effective Time, shall receive a cash payment for the fair value of such fractional share upon the surrender of such stockholders' old stock certificate.
|
|
4.
|
The aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the DGCL.
|
|
5.
|
This Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation shall be effective as of _____ _.m. Eastern time on ____________, 202_.
|
|
|
|
|
|
|||
|
|
|
ENVVENO MEDICAL CORP.
|
||||
|
|
|
By:
|
|
|
||
|
|
|
Name:
|
|
|
Robert Berman
|
|
|
|
|
Title:
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|